medicationNot FDA-approvedRanitidine (Zantac) was withdrawn from the US and several other markets in 2020 after regulators found that NDMA, a probable human carcinogen, could form in the product over time and under storage heatIt was previously available both by prescription and over the counter for ulcer and reflux indications before withdrawalThe cited trials predate the 2020 withdrawal and describe how ranitidine was used when it was an approved therapy
RanitidineBenefits, Dosage & Interactions
Also known as: Zantac
Ranitidine is a medication classified as a histamine H2-receptor antagonist. It works by decreasing the amount of acid produced in the stomach. It is typically taken in the evening. The reported plasma half-life is about 2 hours, which shapes dosing frequency.
How much Ranitidine do people take?
Cited peptic-ulcer healing trials used ranitidine 150 mg twice daily or 300 mg at bedtime; the perioperative reflux-prophylaxis trial used a single preoperative 150 mg oral dose. Route reported: Oral in all three cited trials. Frequency reported: Twice daily or once at bedtime for ulcer healing; single-dose for reflux prophylaxis before surgery. These are amounts documented in the cited studies and labels for Ranitidine — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.
See the full reported protocol and its sourcesResearched by DoseRoutine Research TeamReviewed for accuracy by Nicholas Alexander, RSE, SO, PMPLast updated Educational reference only — not medical advice. Always confirm dosing and safety decisions with a licensed clinician.
Evidence: Strong — 3 human randomized trials published.
Evidence strengthStrong · 4/4
PreclinicalStrong human evidence
3 human randomized trials published.
Plasma half-life
2–3 h
Typical timing
in the evening
Default unit
mg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
- Reported amounts
- Cited peptic-ulcer healing trials used ranitidine 150 mg twice daily or 300 mg at bedtime; the perioperative reflux-prophylaxis trial used a single preoperative 150 mg oral dose[1][2][3]
Reported for Ranitidine in the cited sources. Published ranges are not dosing advice.
References & evidence
Documents the Ranitidine entry is written from. Each number matches an inline marker above.
- [1]Ulcer healing after treatment with sucralfate emulsion or ranitidine. Randomized controlled study in peptic ulcer diseaseLykkegaard Nielsen MC, Vagn Nielsen O, Moesgaard F · Journal of Clinical Gastroenterology · 1988 · Peer-reviewed · PMID 3047220
- [2]Ranitidine versus anticholinergic/antacid for duodenal ulcer. A randomized, endoscopically controlled, single-blind multicentre trialMiettinen P, Anttonen V, Aukee S, Huttunen R, Lahtinen J, Poikolainen E, Pääkkönen M, Tammela T · Scandinavian Journal of Gastroenterology · 1985 · Peer-reviewed · PMID 3898348
- [3]Does ranitidine provide protection against acid gastroesophageal reflux?Verbessem D, Camu F, Van de Velde A · Canadian Journal of Anaesthesia · 1993 · Peer-reviewed · PMID 8425242
References & Evidence
Sources on this page that document Ranitidine dosing, timing and safety.
- [1]U.S. National Library of Medicine View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is Ranitidine?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
Ranitidine is a medication classified as a histamine H2-receptor antagonist. It works by decreasing the amount of acid produced in the stomach. Historically, it was widely used to treat and prevent various conditions associated with excessive stomach acid, including heartburn, acid indigestion, gastroesophageal reflux disease (GERD), and certain types of ulcers, such as peptic ulcer disease and Zollinger-Ellison syndrome (NIH National Library of Medicine, MedlinePlus).
Originally available as both prescription and over-the-counter formulations, Ranitidine has undergone significant regulatory changes due to contamination concerns. In April 2020, the U.S. Food and Drug Administration (FDA) requested manufacturers to withdraw all prescription and over-the-counter ranitidine products from the market in the United States due to detected unacceptable levels of N-Nitrosodimethylamine (NDMA), a probable human carcinogen (FDA announcement). While ranitidine itself is not inherently carcinogenic, the FDA determined that NDMA levels in some ranitidine products could increase over time and when stored at higher than ambient temperatures, leading to potential health risks. Despite its historical efficacy, it is no longer available for use in the U.S. and many other countries. Other H2-receptor antagonists and proton pump inhibitors (PPIs) are now used to manage similar conditions.
What does the research say about Ranitidine?
Tap a section to expand.
Ranitidine primarily functions by blocking histamine H2-receptors located on the parietal cells in the stomach lining. These parietal cells are responsible for secreting hydrochloric acid into the stomach lumen. When histamine binds to H2-receptors, it stimulates a signaling pathway that leads to increased acid production. By competitively blocking these receptors, ranitidine prevents histamine from activating the parietal cells, thereby reducing both the volume of gastric acid secreted and its concentration (PubChem, DrugBank). This action is non-competitive, meaning ranitidine blocks the binding of histamine without activating the receptor itself.
This reduction in stomach acid helps to alleviate symptoms associated with hyperacidity and provides a more favorable environment for the healing of ulcers and esophageal erosions. Unlike antacids, which neutralize existing stomach acid, ranitidine works pro-actively to decrease the *production* of stomach acid. Its effects generally last longer than those of antacids, providing more sustained relief (MedlinePlus).
Source for this section: Sources for How does Ranitidine work?: Jumps to this entry in the sources and references list at the end of the page.
Before its withdrawal from the market, ranitidine provided several therapeutic benefits related to inhibiting stomach acid production:
* **Relief of Heartburn and Acid Indigestion:** It effectively reduced symptoms of occasional heartburn and sour stomach by lowering gastric acid levels (MedlinePlus).
* **Treatment of Gastroesophageal Reflux Disease (GERD):** By decreasing acid reflux into the esophagus, ranitidine helped manage GERD symptoms and allowed esophageal tissue to heal (Mayo Clinic).
* **Healing of Stomach and Duodenal Ulcers:** It created an environment conducive to the healing of peptic ulcers by reducing acid-induced irritation and damage to the stomach and duodenal lining (DrugBank).
* **Prevention of Stress Ulcers:** For hospitalized patients at high risk, it was sometimes used to prevent stress-induced gastric ulcers.
* **Management of Zollinger-Ellison Syndrome:** In this rare condition characterized by excessive acid secretion due to a tumor, ranitidine helped control acid output (NIH National Library of Medicine).
* **Prevention of Acid Aspiration Syndrome:** In certain clinical settings, it was used to reduce gastric acid volume and acidity prior to surgery to minimize the risk of acid aspiration into the lungs.
It is critical to note that while these benefits were well-established, ranitidine is no longer available due to safety concerns related to N-Nitrosodimethylamine (NDMA) contamination (FDA announcement).
The efficacy of ranitidine has been supported by numerous clinical studies conducted prior to its market withdrawal. For instance, a systematic review published in the Cochrane Database of Systematic Reviews evaluated H2-receptor antagonists, including ranitidine, for the treatment of peptic ulcers and found significant evidence for their effectiveness in healing both gastric and duodenal ulcers when compared to placebo. Studies consistently demonstrated that ranitidine was effective in reducing stomach acid secretion and providing symptomatic relief for conditions like heartburn and gastroesophageal reflux disease (GERD) (Cochrane Library).
Further evidence from randomized controlled trials over several decades confirmed its role in the management of specific hypersecretory conditions such as Zollinger-Ellison Syndrome, where robust acid suppression is critical. Its ability to reduce gastric acid output significantly was well-documented in pharmacological studies (PubChem). The sustained popularity and wide usage of ranitidine, both as a prescription and over-the-counter medication, until its withdrawal, further underscores the broad clinical acceptance of its acid-reducing properties based on extensive research and patient experience (Examine.com). This extensive body of evidence contributed to its position as a first-line treatment for various acid-related disorders for many years.
Commonly reported side effects of ranitidine, when it was available, were generally mild and infrequent. These included:
* Headache
* Constipation or diarrhea
* Nausea
* Stomach pain
* Dizziness
Less commonly, some individuals experienced more significant side effects such as fatigue, insomnia, or skin rash. Rare but serious side effects reported with ranitidine in medical literature (e.g., DrugBank, MedlinePlus) included:
* Liver problems (e.g., hepatitis, jaundice)
* Blood disorders (e.g., thrombocytopenia, agranulocytosis)
* Central nervous system effects (e.g., confusion, hallucinations), particularly in older adults or those with kidney impairment
* Cardiovascular effects (e.g., bradycardia, tachycardia), especially with intravenous administration
* Hypersensitivity reactions (e.g., rash, swelling, anaphylaxis)
It is important to reiterate that while these side effects were associated with the mediation itself, the primary reason for ranitidine's removal from the market is the potential formation of N-Nitrosodimethylamine (NDMA), a probable human carcinogen, within the product over time (FDA announcement). This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Source for this section: Sources for What are the side effects of Ranitidine?: Jumps to this entry in the sources and references list at the end of the page.
Prior to its withdrawal from the market, several warnings and precautions were associated with ranitidine use. Patients with kidney dysfunction or severe liver disease often required dosage adjustments due to altered drug metabolism and excretion (DrugBank). It was advised to use ranitidine with caution in patients with acute porphyria, as it was considered possibly porphyrinogenic. There were also warnings regarding potential central nervous system effects, such as confusion or hallucinations, especially in elderly patients or those with pre-existing kidney or liver impairment (MedlinePlus).
Masking of symptoms of serious underlying conditions, such as gastric malignancy, was another concern, as symptom relief from ranitidine could delay diagnosis. Thus, careful diagnostic evaluation was recommended for patients with recurrent acid indigestion. Additionally, rare but serious cardiac arrythmias had been reported, particularly with rapid intravenous administration. The most critical warning, however, emerged more recently regarding the presence of N-Nitrosodimethylamine (NDMA), a probable human carcinogen, in ranitidine products, leading to its global market withdrawal (FDA announcement). This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Source for this section: Sources for Who should avoid Ranitidine?: Jumps to this entry in the sources and references list at the end of the page.
Ranitidine was generally contraindicated in individuals with a known hypersensitivity to ranitidine or any other component of the formulation. A history of an allergic reaction to other H2-receptor antagonists (like famotidine, cimetidine, or nizatidine) was also considered a potential contraindication due to the possibility of cross-reactivity, though this was rare (DrugBank).
Additionally, due to its metabolic pathways and potential for accumulation, it was generally contraindicated or required significant dose adjustments in patients with severe renal impairment. While not an absolute contraindication, its use in patients with acute porphyria was generally advised against or approached with extreme caution due to concerns about exacerbating the condition (MedlinePlus).
It is paramount to emphasize that ranitidine is no longer available on the market due to the presence of N-Nitrosodimethylamine (NDMA), a probable human carcinogen, in its formulations (FDA announcement). Therefore, its use is now contra-indicated for all individuals irrespective of their health status. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Source for this section: Sources for When should Ranitidine not be taken?: Jumps to this entry in the sources and references list at the end of the page.
When ranitidine was available, several drug interactions were noted that could either reduce its effectiveness or increase the risk of side effects. These interactions mainly stemmed from ranitidine's effect on stomach acid, which can alter the absorption of other medications, and its metabolism (DrugBank).
* **Drugs requiring an acidic environment for absorption:** Ranitidine could decrease the absorption of medications like ketoconazole, itraconazole, and certain antivirals (e.g., atazanavir, delavirdine), making them less effective (MedlinePlus).
* **Warfarin:** Although rare, there were reports of altered prothrombin time with concomitant use of ranitidine and warfarin, necessitating closer monitoring of INR levels.
* **Procainamide:** Ranitidine could potentially increase the plasma levels of procainamide, a heart medication, by reducing its renal clearance, leading to an increased risk of toxicity.
* **Antacids:** While often used together for immediate relief, antacids could reduce the absorption of ranitidine if taken concurrently. It was usually recommended to separate their administration by at least an hour.
* **CYP450 metabolized drugs:** Ranitidine has minimal effect on the cytochrome P450 enzyme system, unlike cimetidine, but some interactions could still occur.
Despite these historical interactions, the crucial point is that ranitidine is no longer available for use due to safety concerns regarding N-Nitrosodimethylamine (NDMA) contamination (FDA announcement). This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Source for this section: Sources for What should you not mix with Ranitidine?: Jumps to this entry in the sources and references list at the end of the page.
Ranitidine was typically taken either with or without food. For conditions like episodic heartburn or indigestion, it could be taken as needed to alleviate symptoms. For the treatment of ulcers or GERD, it was often prescribed as a twice-daily dose, for example, once in the morning and once in the evening. Some formulations were designed for once-daily dosing, often taken at bedtime to suppress nocturnal acid secretion, which is a common contributor to ulcer pain (Mayo Clinic, MedlinePlus). The specific timing and frequency depended on the condition being treated and the formulation used. As ranitidine is no longer available, these timing guidelines are historical.
Put it into practice
Reading about Ranitidine is the first step — DoseRoutine helps you act on it. These free tools turn what you just learned into a routine.
What interacts with Ranitidine?
Frequently asked questions about Ranitidine
Ranitidine was used to treat and prevent various conditions involving excess stomach acid, including heartburn, acid indigestion, gastroesophageal reflux disease (GERD), and certain types of ulcers like peptic ulcers and Zollinger-Ellison syndrome (NIH National Library of Medicine).
Ranitidine products were recalled and removed from the market globally due to concerns over the potential for N-Nitrosodimethylamine (NDMA), a probable human carcinogen, to form in the drug at unacceptable levels, especially under certain storage conditions (FDA announcement).
Yes, there are several alternative medications available that work similarly or differently to reduce stomach acid. These include other H2-receptor antagonists (like famotidine) and proton pump inhibitors (such as omeprazole, lansoprazole, and esomeprazole). Antacids can also provide immediate, short-term relief (Mayo Clinic).
No, ranitidine and famotidine are both H2-receptor antagonists that reduce stomach acid, but they are distinct chemical compounds. Famotidine (Pepcid) remains available on the market and has not been subject to the same NDMA contamination concerns as ranitidine (DrugBank).
No, ranitidine is no longer legally available for sale in the United States and many other countries due to regulatory actions citing safety concerns related to NDMA contamination (FDA announcement).
As a medication, Ranitidine can overlap with other supplements, prescription medicines, hormones and peptides. Because Ranitidine is usually taken in the evening, most avoidable conflicts come from what else lands in that same window. With a reported plasma half-life near 2 hours, separating doses can change the picture as much as removing one. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers Ranitidine with no sign-up.
Ranitidine is typically taken in the evening. The reported plasma half-life is about 2 hours, which is what drives how often it is redosed. Amounts for this medication vary by protocol, formulation and individual response, so follow the dose your clinician or the product label specifies.
Whether Ranitidine fits alongside testosterone replacement therapy depends on the protocol — dose, ester and ancillaries such as HCG or anastrozole — and on current bloodwork. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
"Peptides" is not one category — healing peptides, GLP-1 agonists, growth-hormone secretagogues and melanocortins each behave differently next to Ranitidine. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
A short plasma half-life of roughly 2 hours is why protocols often split Ranitidine across the day rather than using a single dose. It is typically taken in the evening. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
Because Ranitidine clears quickly (plasma half-life around 2 hours), a missed dose leaves a real gap in exposure rather than being buffered by what is still in your system. Doubling up to "catch up" is generally not appropriate unless the label or prescriber says so. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For Ranitidine the useful record is the dose, the time it was actually taken, and what else was taken in the same window. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
Cited peptic-ulcer healing trials used ranitidine 150 mg twice daily or 300 mg at bedtime; the perioperative reflux-prophylaxis trial used a single preoperative 150 mg oral dose. Route reported: Oral in all three cited trials. Frequency reported: Twice daily or once at bedtime for ulcer healing; single-dose for reflux prophylaxis before surgery. These are amounts documented in the cited studies and labels for Ranitidine — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.
Which studies looked at Ranitidine?
Peer-reviewed research indexed in PubMed. Each entry links to the original record.
- 1.Ranitidine(opens PubMed in a new tab)JAMA · 1983 · PMID 6312110 · https://pubmed.ncbi.nlm.nih.gov/6312110/
- 2.Interactions and non-interactions with ranitidine(opens PubMed in a new tab)Clin Pharmacokinet · 1984 · PMID 6096071 · https://pubmed.ncbi.nlm.nih.gov/6096071/
- 3.Clinical pharmacokinetics of ranitidine.(opens PubMed in a new tab)Clinical pharmacokinetics · 1984 · PMID 6329583 · https://pubmed.ncbi.nlm.nih.gov/6329583/
- 4.Systematic review and meta-analysis: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics in Helicobacter pylori eradication(opens PubMed in a new tab)Helicobacter · 2005 · PMID 15904473 · https://pubmed.ncbi.nlm.nih.gov/15904473/
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- MedlinePlus(opens in a new tab)U.S. National Library of Medicine · medlineplus.gov/druginfo/meds/a601106.html
Verify at
Publisher search links for Ranitidine. These are places to check the information — they are not citations, so they are not numbered.
- FDA-approved labeling (DailyMed)(publisher search, opens in a new tab)U.S. Food and Drug Administration · publisher search
- PubChem(publisher search, opens in a new tab)National Center for Biotechnology Information · publisher search
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- Mayo Clinic(publisher search, opens in a new tab)Mayo Clinic · publisher search
- Cochrane Library(publisher search, opens in a new tab)Cochrane · publisher search
- Examine.com(publisher search, opens in a new tab)Examine.com · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- Wikipedia entry(publisher search, opens in a new tab)Wikipedia · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on Ranitidine?
Plain-text summary, safe to quote verbatim:
Ranitidine is a medication classified as a histamine H2-receptor antagonist. It works by decreasing the amount of acid produced in the stomach. It is typically taken in the evening. The reported plasma half-life is about 2 hours, which shapes dosing frequency.
Source: DoseRoutine — https://doseroutine.com/library/ranitidine
Ranitidine cheat sheet
DoseRoutine cheat sheet · Medication
Ranitidine
Ranitidine is a medication classified as a histamine H2-receptor antagonist. It works by decreasing the amount of acid produced in the stomach.
Evidence
Strong
3 human randomized trials published.
Studied range
Cited peptic-ulcer healing trials used ranitidine 150 mg twice daily or 300 mg at bedtime; the perioperative reflux-prophylaxis trial used a single preoperative 150 mg oral dose
Route
Oral in all three cited trials
Frequency studied
Twice daily or once at bedtime for ulcer healing; single-dose for reflux prophylaxis before surgery
Half-life
2–3 h
Timing
in the evening
Not FDA-approvedRanitidine (Zantac) was withdrawn from the US and several other markets in 2020 after regulators found that NDMA, a probable human carcinogen, could form in the product over time and under storage heatIt was previously available both by prescription and over the counter for ulcer and reflux indications before withdrawalThe cited trials predate the 2020 withdrawal and describe how ranitidine was used when it was an approved therapy
Key references
- Ulcer healing after treatment with sucralfate emulsion or ranitidine. Randomized controlled study in peptic ulcer disease (1988)
- Ranitidine versus anticholinergic/antacid for duodenal ulcer. A randomized, endoscopically controlled, single-blind multicentre trial (1985)
- Does ranitidine provide protection against acid gastroesophageal reflux? (1993)
Studied ranges, not dosing advice. Not medical advice — talk to a clinician. doseroutine.com/library/ranitidine
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). Ranitidine — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/ranitidine
What compounds are similar to Ranitidine?
Others in the medication category or studied for the same goals.